Applied DNA Sciences Q2 EPS $(5.31) Misses $(4.50) Estimate, Sales $929.63K Miss $950.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Applied DNA Sciences (APDN) reported Q2 earnings with a significant miss on both EPS and sales estimates. The EPS was $(5.31), missing the $(4.50) estimate by 18%, and sales were $929.63K, missing the $950.00K estimate by 2.14%. Year-over-year, this represents a 2555% decrease in EPS and a 78.91% decrease in sales.
May 10, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Applied DNA Sciences reported a significant miss in Q2 earnings, with both EPS and sales not meeting analyst expectations. The EPS miss was particularly stark, indicating a substantial decrease in profitability compared to the previous year.
The significant miss in both EPS and sales estimates for APDN, especially the EPS miss by 18%, suggests a substantial underperformance that could negatively impact investor confidence and stock price in the short term. The year-over-year decline further emphasizes the company's current struggles, likely leading to a negative short-term price direction.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100